Mangoceuticals (MGRX) Equity Ratio (2022 - 2026)

Mangoceuticals has disclosed Equity Ratio across 5 years of filings, most recently posting 0.93 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.93, changed 0.19% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.93 (changed 0.19% YoY), and the FY2025 annual result was 0.94, up 4.13% from the prior year.
• Equity Ratio came in at 0.93 for Q1 2026 at Mangoceuticals, down from 0.94 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.95 in Q3 2025 to a low of 3.18 in Q1 2024.
• The 5-year median for Equity Ratio is 0.92 (2025), against an average of 0.59.
• Across the five-year window, Equity Ratio plunged 442.61% in 2024 and soared 129.28% in 2025, its largest moves.
• Mangoceuticals' Equity Ratio stood at 0.61 in 2022, then gained by 20.47% to 0.74 in 2023, then climbed by 23.05% to 0.91 in 2024, then rose by 4.13% to 0.94 in 2025, then dropped by 1.28% to 0.93 in 2026.
• The last three Equity Ratio figures came in at 0.93 (Q1 2026), 0.94 (Q4 2025), and 0.95 (Q3 2025), per Business Quant data.